Zentalis Pharmaceuticals, Inc.ZNTLNASDAQ
LOADING
|||
Alerts
Want to monitor ZNTL?
Get notified when price crosses targets, volume spikes, or RSI hits oversold
Create free account to monitor ZNTLWant to monitor ZNTL?
Get notified when price crosses targets, volume spikes, or RSI hits oversold
Create free account to monitor ZNTLZentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company is developing a broad pipeline of potentially best-in-class oncology candidates, all internally discovered, which include ZN-c5, an oral selective estrogen receptor degrader (SERD) for ER+/HER2- breast cancer, ZN-c3, a WEE1 inhibitor for advanced solid tumors, ZN-d5, a BCL-2 inhibitor for hematologic malignancies, and ZN-e4, an EGFR inhibitor for non-small cell lung carcinoma (NSCLC).